Literature DB >> 22495620

Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats.

Anand Gururajan1, David A Taylor, Daniel T Malone.   

Abstract

Recently, a novel paradigm has been designed to assess social investigative behaviour in pairs of Sprague-Dawley rats, which involves physical separation whilst ensuring they are able to maintain contact through other social cues. We have modified this set-up in order to assess not just social behaviour but also locomotor activity of the rats. Results showed that the MK-801- (0.3 mg/kg) treated rats displayed reduced social investigative behaviour, hyperactivity as well as reduced attention span. Pretreatment with the phytocannabinoid cannabidiol (3 mg/kg) not only normalised social investigative behaviour but increased it beyond control levels. Pretreatment with clozapine (1, 3 mg/kg) also normalised social investigative behaviour. Both cannabidiol and clozapine inhibited MK-801-induced hyperactivity. However, there were no effects of pretreatment on impairments to attention span. Our findings reinforce several aspects of the validity of the MK-801-induced model of social withdrawal and hyperactivity and also support the use of this novel set-up for further investigations to assess the antipsychotic potential of novel compounds.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22495620     DOI: 10.1177/0269881112441865

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  25 in total

1.  Comment on: "Anxiogenic-like effects of chronic cannabidiol administration in rats" (Elbatsh MM, Assareh N, Marsden CA, Kendall DA, Psychopharmacology 2012).

Authors:  Anand Gururajan
Journal:  Psychopharmacology (Berl)       Date:  2012-07-04       Impact factor: 4.530

2.  The group II metabotropic glutamate receptor agonist LY379268 reduces toluene-induced enhancement of brain-stimulation reward and behavioral disturbances.

Authors:  Ming-Huan Chan; Yi-Ling Tsai; Mei-Yi Lee; Astrid K Stoker; Athina Markou; Hwei-Hsien Chen
Journal:  Psychopharmacology (Berl)       Date:  2015-06-06       Impact factor: 4.530

3.  CB2 receptor agonism reverses MK-801-induced disruptions of prepulse inhibition in mice.

Authors:  Ramy Khella; Jennifer L Short; Daniel T Malone
Journal:  Psychopharmacology (Berl)       Date:  2014-04-05       Impact factor: 4.530

Review 4.  Perspectives on zebrafish models of hallucinogenic drugs and related psychotropic compounds.

Authors:  Nikhil Neelkantan; Alina Mikhaylova; Adam Michael Stewart; Raymond Arnold; Visar Gjeloshi; Divya Kondaveeti; Manoj K Poudel; Allan V Kalueff
Journal:  ACS Chem Neurosci       Date:  2013-08-06       Impact factor: 4.418

5.  Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle.

Authors:  Gustavo Gonzalez-Cuevas; Remi Martin-Fardon; Tony M Kerr; David G Stouffer; Loren H Parsons; Dana C Hammell; Stan L Banks; Audra L Stinchcomb; Friedbert Weiss
Journal:  Neuropsychopharmacology       Date:  2018-03-22       Impact factor: 7.853

6.  Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model.

Authors:  Ashleigh L Osborne; Nadia Solowij; Ilijana Babic; Xu-Feng Huang; Katrina Weston-Green
Journal:  Neuropsychopharmacology       Date:  2017-02-23       Impact factor: 7.853

Review 7.  Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders.

Authors:  Alline Cristina Campos; Fabricio Araújo Moreira; Felipe Villela Gomes; Elaine Aparecida Del Bel; Francisco Silveira Guimarães
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

8.  Effects of the fatty acid amide hydrolase inhibitor URB597 on coping behavior under challenging conditions in mice.

Authors:  Jozsef Haller; Mano Aliczki; Katalin Gyimesine Pelczer; Klaudia Spitzer; Zoltan Balogh; Sandor Kantor
Journal:  Psychopharmacology (Berl)       Date:  2013-09-14       Impact factor: 4.530

9.  Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice.

Authors:  Bin Gu; Manhua Zhu; Madison R Glass; Marie Rougié; Viktoriya D Nikolova; Sheryl S Moy; Paul R Carney; Benjamin D Philpot
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

Review 10.  From the Clinic to the Laboratory, and Back Again: Investigations on Cannabinoids and Endocannabinoid System Modulators for Treating Schizophrenia.

Authors:  Kurt Leroy Hoffman
Journal:  Front Psychiatry       Date:  2021-07-05       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.